Tessera Therapeutics
Lorenzo Tozzi has extensive work experience in the field of scientific research. Lorenzo currently holds the position of Principal Scientist at Tessera Therapeutics, starting in March 2022. Prior to this, they worked at bluebird bio from 2018 to 2022, initially as a Scientist I and later as a Scientist II. Before joining bluebird bio, they were a Postdoctoral Fellow at Tufts University from 2013 to 2018. Lorenzo also gained experience as a PostDoc at Università degli Studi di Firenze from 2012 to 2013 and as a Visiting Scientist at CeMM in 2011. These roles allowed him to contribute to various research projects in the fields of hematology and cancer genomics. Overall, Lorenzo Tozzi has a strong background in scientific research and has held positions of increasing responsibility throughout their career.
Lorenzo Tozzi has a Bachelor's degree in Biotechnology from the Università degli Studi di Firenze, which they obtained in 2006. Lorenzo then pursued a Master's degree in Medical Biotechnology from the same university, completing it in 2008. Following that, they earned a Doctor of Philosophy (PhD) degree in Molecular Biology from the Università degli Studi di Firenze in 2012.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.